miR-126在肝癌中表达及其与临床病理特征、预后的关系
|
摘要
目的探讨miR-126在肝癌中表达的临床意义及其与临床特征、预后的关系。方法收集118例肝癌组织、癌旁组织(距肿瘤切缘5 cm的组织)及正常组织(距肿瘤切缘10 cm的组织)标本,应用实时PCR检测miR-126的表达。分析miR-126的表达与肝癌临床病理特征及预后的关系。应用SPSS 19. 0统计软件处理数据,无病生存率行χ2检验;肝组织中miR-126的表达以(x珋±s)表示,行t检验。采用Kaplan-Merier法进行无病生存期分析,运用Cox回归进行单因素及多因素生存分析。P <0. 05差异有统计学意义。结果 miR-126在肝癌组织中的表达量明显低于癌旁组织及正常组织,在癌旁组织中的表达量明显低于正常组织,比较差异具有统计学意义(P <0. 05)。miR-126在肝癌组织中的表达与TNM分期、转移有关(P <0. 05),而与性别、年龄、肿瘤直径、组织类型、肝炎病史、肿瘤数量无关(P> 0. 05)。COX多因素回归模型分析显示,转移、miR-126表达是影响肝癌患者预后的独立因素,其中miR-126低表达患者复发、转移、死亡的风险是miR-126高表达的1. 528倍(95%CI:0. 947～3. 002,P=0. 022)。结论 miR-126表达下调参与了肝癌发生发展过程,对判断肝癌的恶性程度及预测预后有一定的临床价值。
Objective To investigate the clinical significance of miR-126 expression in hepatocellular carcinoma and its relationship with clinical features and prognosis. Methods The expression of miR-126 in118 cases of hepatocellular carcinoma and its respective adjacent tissue were detected by using real-time PCR.The relationship between the expression of miR-126 and the clinicopathological features and prognosis of hepatocellular carcinoma was analyzed by usingstatistical software SPSS 19. 0. Measurement data such as expression of miR-126 were expressed as mean ± standard deviation( x珋± s),and independent t test was used for comparison between the groups. Disease-Free-Survival( DFS) were examined by using Kaplan-Merier method and Cox regression analysis. A P value < 0. 05 was considered as statistically significant difference.Results The expression of miR-126 in liver cancer tissues was significantly lower than that of normal liver tissue,and the expression in the metastatic liver cancer tissues was significantly lower than that of the non metastatic liver cancer tissues,with significant difference( P < 0. 05). The expression of miR-126 in liver cancer tissues was related to TNM staging and metastasis( P < 0. 05),but not related to sex,age,tumor diameter,tissue type,history of hepatitis and the number of tumors( P > 0. 05). Cox multiple regression model analysis showed that metastasis and miR-126 expression were independent factors affecting the prognosis of patients with liver cancer,and the risk of recurrence,metastasis and death of patients with miR-126 low expression was 1. 528 times higher than that of patients with miR-126 high expression( 95% CI: 0. 947 to3. 002,P = 0. 022). Conclusion The down-regulation of miR-126 is involved in the carcinogenesis and progression of HCC,and has a certain clinical value in judging the malignancy and prognosis of HCC.
Objective To investigate the clinical significance of miR-126 expression in hepatocellular carcinoma and its relationship with clinical features and prognosis. Methods The expression of miR-126 in118 cases of hepatocellular carcinoma and its respective adjacent tissue were detected by using real-time PCR.The relationship between the expression of miR-126 and the clinicopathological features and prognosis of hepatocellular carcinoma was analyzed by usingstatistical software SPSS 19. 0. Measurement data such as expression of miR-126 were expressed as mean ± standard deviation( x珋± s),and independent t test was used for comparison between the groups. Disease-Free-Survival( DFS) were examined by using Kaplan-Merier method and Cox regression analysis. A P value < 0. 05 was considered as statistically significant difference.Results The expression of miR-126 in liver cancer tissues was significantly lower than that of normal liver tissue,and the expression in the metastatic liver cancer tissues was significantly lower than that of the non metastatic liver cancer tissues,with significant difference( P < 0. 05). The expression of miR-126 in liver cancer tissues was related to TNM staging and metastasis( P < 0. 05),but not related to sex,age,tumor diameter,tissue type,history of hepatitis and the number of tumors( P > 0. 05). Cox multiple regression model analysis showed that metastasis and miR-126 expression were independent factors affecting the prognosis of patients with liver cancer,and the risk of recurrence,metastasis and death of patients with miR-126 low expression was 1. 528 times higher than that of patients with miR-126 high expression( 95% CI: 0. 947 to3. 002,P = 0. 022). Conclusion The down-regulation of miR-126 is involved in the carcinogenesis and progression of HCC,and has a certain clinical value in judging the malignancy and prognosis of HCC.
引文
[1]陈孝平,张万广.腹腔镜肝癌根治术的难点与争议[J/CD].中华普外科手术学杂志(电子版),2018,12(5):361-363.
[2]刘双勇,吴德全.肝癌术后复发转移原因及治疗现状[J].疑难病杂志,2018,17(3):311-314.
[3]王锐,任洋,杨婧.中药调控下的miRNA差异表达抑制肝癌研究进展[J].中国药学杂志,2018,53(3):169-173.
[4] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012:Global Cancer Statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[5]叶建蔚,苗娜,刘辉,等.泡球蚴感染中期小鼠肝脏中miR-100/125b/126/122的表达变化[J].中国病原生物学杂志,2013,8(5):417-422.
[6]米旭光,李首庆,刘多,等. miR-126在乳腺癌中与VEGF表达关系及其抗肿瘤效果[J].中国免疫学杂志,2016,32(7):1000-1003.
[7]刘星烁,李红雨,赵书君,等.上皮性卵巢癌组织中miR-126、EGFL7的表达与微血管密度的检测[J].郑州大学学报(医学版),2015,50(2):244-248.
[8]夏铭蔚,邵正斌,梁国庆,等.冠心病患者血浆中miR-126水平与其冠状动脉侧支循环系统形成及预后的关系[J].广东医学,2018,39(14):2179-2182.
[9]马寅芙,李首庆,米旭光,等. miR-126和miR-199对乳腺癌细胞周期进程的影响[J].中国实验诊断学,2017,21(10):1828-1830.
[10] Zhang W,Zhou J,Zhu X,et al. MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer[J]. Gene,2017,627:420-427.
[11]阮之平,徐瑞,经里,等. MiR-126抑制肝癌细胞增殖的实验研究[J].现代肿瘤医学,2015,23(14):1947-1952.
[12]彭吉祥,王小康,林卓远,等.微小RNA-126对肝癌细胞增殖、凋亡、侵袭及转移的影响[J].中华实验外科杂志,2015,32(7):1619-1621.
[13]毛顺宝,马筱秋,王霖沛.结肠癌微小RNA-126的表达情况及其与高尔基体磷酸化蛋白3的关系[J].广西医学,2018,40(14):1575-1578.
[14]何华,黄毓,杨定华,等. miR-126/miR-126*在肝细胞癌中的表达及其与临床预后的相关性[J].南方医科大学学报,2014,34(10):1493-1497.
[15]孟玮,宗治国,史晓宇,等. miR-126对结肠癌SW480细胞增殖、凋亡、周期及SOX2表达的影响[J].中国比较医学杂志,2018,28(4):93-97.
[16]周争光,汪蕊,李玉梅,等. mir-130a-3p及smad 4在肝细胞癌组织中的表达及临床意义[J].安徽医科大学学报,2017,52(3):383-387.
[17]郑茜,张勇,杨东伟. MiR-126通过MAPK信号通路抑制ox LDL处理的血管平滑肌细胞增殖和迁移[J].中国免疫学杂志,2018,34(2):192-198.
[18]魏海峰,米旭光,刘磊,等. miR-126对结肠癌细胞生物学行为的影响及其在调控结肠癌EMT转化中的作用[J].中国免疫学杂志,2017,33(11):1658-1661.
[2]刘双勇,吴德全.肝癌术后复发转移原因及治疗现状[J].疑难病杂志,2018,17(3):311-314.
[3]王锐,任洋,杨婧.中药调控下的miRNA差异表达抑制肝癌研究进展[J].中国药学杂志,2018,53(3):169-173.
[4] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012:Global Cancer Statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[5]叶建蔚,苗娜,刘辉,等.泡球蚴感染中期小鼠肝脏中miR-100/125b/126/122的表达变化[J].中国病原生物学杂志,2013,8(5):417-422.
[6]米旭光,李首庆,刘多,等. miR-126在乳腺癌中与VEGF表达关系及其抗肿瘤效果[J].中国免疫学杂志,2016,32(7):1000-1003.
[7]刘星烁,李红雨,赵书君,等.上皮性卵巢癌组织中miR-126、EGFL7的表达与微血管密度的检测[J].郑州大学学报(医学版),2015,50(2):244-248.
[8]夏铭蔚,邵正斌,梁国庆,等.冠心病患者血浆中miR-126水平与其冠状动脉侧支循环系统形成及预后的关系[J].广东医学,2018,39(14):2179-2182.
[9]马寅芙,李首庆,米旭光,等. miR-126和miR-199对乳腺癌细胞周期进程的影响[J].中国实验诊断学,2017,21(10):1828-1830.
[10] Zhang W,Zhou J,Zhu X,et al. MiR-126 reverses drug resistance to TRAIL through inhibiting the expression of c-FLIP in cervical cancer[J]. Gene,2017,627:420-427.
[11]阮之平,徐瑞,经里,等. MiR-126抑制肝癌细胞增殖的实验研究[J].现代肿瘤医学,2015,23(14):1947-1952.
[12]彭吉祥,王小康,林卓远,等.微小RNA-126对肝癌细胞增殖、凋亡、侵袭及转移的影响[J].中华实验外科杂志,2015,32(7):1619-1621.
[13]毛顺宝,马筱秋,王霖沛.结肠癌微小RNA-126的表达情况及其与高尔基体磷酸化蛋白3的关系[J].广西医学,2018,40(14):1575-1578.
[14]何华,黄毓,杨定华,等. miR-126/miR-126*在肝细胞癌中的表达及其与临床预后的相关性[J].南方医科大学学报,2014,34(10):1493-1497.
[15]孟玮,宗治国,史晓宇,等. miR-126对结肠癌SW480细胞增殖、凋亡、周期及SOX2表达的影响[J].中国比较医学杂志,2018,28(4):93-97.
[16]周争光,汪蕊,李玉梅,等. mir-130a-3p及smad 4在肝细胞癌组织中的表达及临床意义[J].安徽医科大学学报,2017,52(3):383-387.
[17]郑茜,张勇,杨东伟. MiR-126通过MAPK信号通路抑制ox LDL处理的血管平滑肌细胞增殖和迁移[J].中国免疫学杂志,2018,34(2):192-198.
[18]魏海峰,米旭光,刘磊,等. miR-126对结肠癌细胞生物学行为的影响及其在调控结肠癌EMT转化中的作用[J].中国免疫学杂志,2017,33(11):1658-1661.